Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.
Also called NCT05164263
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,000 participants
- Sponsor
- Registry
-
NCT05164263
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Afghanistan, Kenya, Nigeria, Pakistan, Sri Lanka
- Registry status
- Recruiting
Technical summary
Registry record NCT05164263. Allocation not applicable; no masking; primary purpose treatment. Start 2021-04-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study
- Acronym
- EASE
- Condition
- Type II Diabetes Mellitus
- Condition
- Efficacy, Self
- Condition
- Safety Issues
- Intervention (Drug)
- Empagliflozin
- Lead sponsor
- Getz Pharma
Record details
- Record id
cardio:ct-nct05164263- Content hash
4a6a5e18439e710d1bc40aa353124e2f3702b5cf450b800dfcea9442966e6f18